

03CO

JAN 21 2004

**TRANSMITTAL LETTER
(General - Patent Pending)**

Docket No.
85761-28

In Application Of: DUBOIS, Claire

Serial No. 09/885,914	Filing Date June 22, 2001	Examiner Not assigned	Group Art Unit 1614
--------------------------	------------------------------	--------------------------	------------------------

Title: **USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT OF
INFLAMMATORY OR MATRIX REMODELLING DISEASES**

TO THE DIRECTOR OF THE UNITED STATES PATENT AND TRADEMARK OFFICE:

Transmitted herewith is:

1. Associate Power of Attorney or Agent (37 CFR 1.34);
2. A copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
3. Amendment and Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures;
4. 2 pages of Sequence Listing; 5. Diskette containing computer-readable copy of Sequence Listing.

- ☒ No additional fee is required.
- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **19-2550** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.


Signature

Dated: **January 20, 2004**

**S. Serge Shahinian, Reg. No. 52,533
SMART & BIGGAR
1000 de la Gauchetière Street West
Suite 3400
Montreal, Quebec
H3B 4W5
CANADA**

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

CC:



**Associate Power Of Attorney Or Agent (37 CFR 1.34)
(For Representation Related To A Patent Application)**

Docket No.
85761-28

In Re Application Of: **DUBOIS, Claire**

Serial No.
09/885,914

Filing Date
June 22, 2001

Examiner
Not assigned

Group Art Unit
1614

Invention: **USE OF FURIN AND FURIN-LIKE PROTEASE INHIBITORS IN THE TREATMENT
OF INFLAMMATORY OR MATRIX REMODELLING DISEASES**

TO THE COMMISSIONER FOR PATENTS:

Please recognize the following as ☐ Associate Attorney ☒ Associate Agent in this application.

Name: **S. Serge Shahinian**

Reg. No.: **52,533**

Address: **SMART & BIGGAR
1000 de la Gauchetière Street West
Suite 3400
Montreal, Quebec
H3B 4W5
CANADA**

Tel. No. **(514) 954-1500**


Signature of Principal Attorney or Agent of Record

Dated: **January 8, 2004**

**Stephan P. Georgiev, Reg. No. 37,563
SMART & BIGGAR
1000 de la Gauchetière Street West
Suite 3400
Montreal, Quebec
H3B 4W5
CANADA**

Registration Number & Address of Principal Attorney or Agent of Record

I certify that this document is being deposited on
with the U.S. Postal Service as first
class mail under 37 C.F.R. 1.8 and is addressed to the
Commissioner for Patents, P.O. Box 1450, Alexandria, VA
22313-1450.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/885,914	06/22/2001	Claire Dubois	85761-28

Stephen P. Georgiev
 SMART & BIGGAR
 Suite 3400
 1000 de la Gauchetiere Street West
 Montreal, QC H3B 4W5
 CANADA



CONFIRMATION NO. 5893

FORMALITIES LETTER



OC000000011349281

Date Mailed: 11/24/2003

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).


- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts
 Commissioner for Patents
 P.O. Box 1450
 Alexandria VA 22313-1450

*A copy of this notice **MUST** be returned with the reply.*

A handwritten signature in dark ink, appearing to be 'AB', is positioned above a horizontal line.

Customer Service Center
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE